Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel

Biomaterials

Volumn 32, Issue 22, 2011, Pages 5123-5133

  Shahin, Mostafa ^a   Ahmed, Sahar ^a   Kaur, Kamaljit ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Active targeting; C(RGDfK); P160 peptide; Paclitaxel; Peptide ligand; Polymeric micelles

Indexed keywords

ACTIVE TARGETING; C(RGDFK); P160 PEPTIDE; PACLITAXEL; PEPTIDE LIGAND; POLYMERIC MICELLE;

BLOCK COPOLYMERS; CARBOXYLATION; CELL CULTURE; DIALYSIS; DISEASES; ENDOTHELIAL CELLS; ETHYLENE; LIGANDS; PEPTIDES; POLYETHYLENE OXIDES; POLYMERS;

MICELLES;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ARGINYLGLYCYLASPARTIC ACID; COPOLYMER; FLUORESCENT DYE; LIGAND; PACLITAXEL; PEPTIDE; POLY(ETHYLENE OXIDE) B POLY(ALPHA BENZYL CARBOXYLATE EPSILON CAPROLACTONE); POLY(ETHYLENE OXIDE) B POLY(EPSILON CAPROLACTONE); UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; INTERNALIZATION; MICELLE; PRIORITY JOURNAL; TECHNIQUE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LACTONES; LIGANDS; MATERIALS TESTING; MICELLES; MOLECULAR STRUCTURE; NEOPLASMS; PACLITAXEL; PEPTIDES; POLYESTERS; POLYETHYLENE GLYCOLS;

EID: 79956105100     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.03.061     Document Type: Article

References (33)

1. Temming K., Schiffelers R., Molema G., Kok R. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005, 8(6):381-402.
2. Aina O.H., Liu R., Sutcliffe J.L., Marik J., Pan C.X., Lam K.S. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007, 4(5):631-651.
3. Aina O.H., Sroka T.C., Chen M.L., Lam K.S. Therapeutic cancer targeting peptides. Biopolymers 2002, 66(3):184-199.
4. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
5. Chen X., Plasencia C., Hou Y., Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005, 48(4):1098-1106.
6. Mukhopadhyay S., Barnes C.M., Haskel A., Short S.M., Barnes K.R., Lippard S.J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem 2008, 19(1):39-49.
7. Nasongkla N., Shuai X., Ai H., Weinberg B.D., Pink J., Boothman D.A., et al. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl 2004, 43(46):6323-6327.
8. Schiffelers R.M., Koning G.A., ten Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003, 91(1-2):115-122.
9. Xiong X.B., Huang Y., Lu W.L., Zhang H., Zhang X., Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res 2005, 22(6):933-939.
10. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 2005, 94(8):1782-1793.
11. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005, 107(2):262-275.
12. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Zhang Q. Preparation of doxorubicin-loaded stealth liposomes modified with RGD mimetic and cellular association in vitro. Yao Xue Xue Bao 2005, 40(12):1085-1090.
13. Hu Z., Luo F., Pan Y., Hou C., Ren L., Chen J., et al. Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. J Biomed Mater Res A 2008, 85(3):797-807.
14. Garde S.V., Forte A.J., Ge M., Lepekhin E.A., Panchal C.J., Rabbani S.A., et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007, 18(10):1189-1200.
15. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006, 66(20):10073-10082.
16. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003, 63(21):7400-7409.
17. Kessler H., Diefenbach B., Finsinger D., Geyer A., Gurrath M., Goodman S.L., et al. Design of superactive and selective integrin receptor antagonists containing the RGD sequence. Lett Pep Sci 1995, 2(3):155-160.
18. Haubner R., Gratias R., Diefenbach B., Goodman S., Jonczyk A., Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin v 3 antagonists. J Am Chem Soc 1996, 118(32):7461-7472.
19. Wilder R.L. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002, 61(Suppl. 2:ii):96-99.
20. Nemeth J.A., Cher M.L., Zhou Z., Mullins C., Bhagat S., Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003, 20(5):413-420.
21. Curnis F., Arrigoni G., Sacchi A., Fischetti L., Arap W., Pasqualini R., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002, 62(3):867-874.
22. Colombo G., Curnis F., De Mori G.M., Gasparri A., Longoni C., Sacchi A., et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 2002, 277(49):47891-47897.
23. Zhang J., Spring H., Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett 2001, 171(2):153-164.
24. Shahin M., Lavasanifar A. Novel self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery. Int J Pharm 2010, 389(1-2):213-222.
25. Xiong X.B., Mahmud A., Uludag H., Lavasanifar A. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells. Biomacromolecules 2007, 8(3):874-884.
26. Xiong X.B., Mahmud A., Uludag H., Lavasanifar A. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells. Pharm Res 2008, 25(11):2555-2566.
27. Mahmud A., Lavasanifar A. The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells. Colloids Surf B Biointerfaces 2005, 45(2):82-89.
28. Forrest M.L., Yanez J.A., Remsberg C.M., Ohgami Y., Kwon G.S., Davies N.M. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 2008, 25(1):194-206.
29. Askoxylakis V., Zitzmann S., Mier W., Graham K., Kramer S., von Wegner F., et al. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res 2005, 11(18):6705-6712.
30. Tseng Y.L., Liu J.J., Hong R.L. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol 2002, 62(4):864-872.
31. Wang T., Petrenko V.A., Torchilin V.P. Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm 2010, 7(4):1007-1014.
32. Danhier F., Vroman B., Lecouturier N., Crokart N., Pourcelle V., Freichels H., et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release 2009, 140(2):166-173.
33. Yin J., Li Z., Yang T., Wang J., Zhang X., Zhang Q. Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature. J Drug Target 2011, 19(1):25-36.